INSULIN LISPRO (in'su-lyn lis'pro) Humalog Classifications: hormone and synthetic substitute; antidiabetic agent; insulin rapid-acting; Therapeutic: antidiabetic; insulin rapid-acting Prototype: Insulin injection Pregnancy Category: B |
100 units/mL
Insulin lispro of recombinant DNA origin is a human insulin that is a rapid-acting, glucose-lowering agent of shorter duration than human regular insulin. It lowers blood glucose levels by increasing peripheral glucose uptake, especially by skeletal muscle and fat tissue, and by inhibiting the liver from changing glycogen to glucose.
It lowers blood glucose levels and inhibits liver from changing glycogen to glucose.
Treatment of diabetes mellitus.
During episodes of hypoglycemia or in patients sensitive to any ingredient in the formulation; intravenous administration.
In insulin-resistant patients, hyperthyroidism or hypothyroidism; older adults, renal or hepatic impairment; children, pregnancy (category B), lactation.
Diabetes Mellitus (type 1) Adult: SC 510 U 015 min a.c. (dose adjustments based on blood glucose determinations) |
(see INSULIN INJECTION, REGULAR)
Assessment & Drug Effects
Patient & Family Education